These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 39149756)

  • 1. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    Peng J; Xu H; Liu Q
    PLoS One; 2024; 19(10):e0312133. PubMed ID: 39423210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.
    Wei J; Xu K; Lin Y; Liu Q; Zhou C; Zhang P; Ma R; Zhang M; Zhang L; Li X
    Int J Clin Pharm; 2024 Oct; 46(5):1189-1199. PubMed ID: 38814514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
    Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
    Fleeman N; Houten R; Nevitt S; Mahon J; Beale S; Boland A; Greenhalgh J; Edwards K; Maden M; Bhattacharyya D; Chaplin M; McEntee J; Chow S; Waddell T
    Health Technol Assess; 2024 Aug; 28(49):1-190. PubMed ID: 39252678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
    Lang W; Deng L; Huang B; Zhong D; Zhang G; Lu M; Ouyang M
    Clin Drug Investig; 2024 Mar; 44(3):149-162. PubMed ID: 38300386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
    Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
    BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Liu K; Zhu Y; Zhu H
    Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
    Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
    Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
    Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
    BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China.
    Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S
    J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
    Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
    Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
    Changez MIK; Khan M; Uzair M; Tahir MF; Mohsin M; Hussain AF; Saqib V; Molani MK; Ahmed AH; Khalid S
    J Gastrointest Cancer; 2024 Mar; 55(1):467-481. PubMed ID: 38095799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
    Wang X; Sun X; Lei Y; Fang L; Wang Y; Feng K; Xia F
    BMC Cancer; 2024 Aug; 24(1):1036. PubMed ID: 39174912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
    Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
    Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.